What question did this study set out to answer?

To critically examine regulatory qualification and physicochemical characterization hurdles for nanomedicines under the current European regulatory system and evaluate pathways for quality assurance.

September 17, 2023Advanced Healthcare MaterialsOpen Access

Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges

View Full Paper

Ask AI

Bookmark

Authors

UMUmberto M. MusazziUniversity of Milan SFSilvia FranzèUniversity of Milan FCFabrizio CondorelliPiedmont University

Discussion

Member takes

Implication

Critical review reveals regulatory and quality characterization gaps for nanomedicines in Europe, highlighting the need for AI-driven predictive modeling and standardized frameworks.

Key Points

To critically examine regulatory qualification and physicochemical characterization hurdles for nanomedicines under the current European regulatory system and evaluate pathways for quality assurance.
Evaluated current European pharmaceutical regulatory frameworks concerning quality, safety, and market authorization of nanomedicines.
Examined interdisciplinary approaches involving standardized characterization, artificial intelligence, and digital predictive modeling to forecast in vivo behavior.
Identified that structural complexity and unique physicochemical attributes create significant hurdles for assessing efficacy, safety, and benefit/risk profiles under non-standardized definitions.
Determined that establishing collaborative alliances across academia, industry, and regulatory bodies is necessary to implement standardized qualification and risk assessment frameworks.
Showed that integrating artificial intelligence and digital modeling tools provides actionable strategies for predicting in vivo distribution and improving quality assurance.

Cite This Study

Musazzi et al. (2023) studied this question.

synapsesocial.com/papers/6a7fda32f0b2a14a267ddf0b https://doi.org/10.1002/adhm.202301956

View Full Paper

Ask AI

Bookmark

Implication

Critical review reveals regulatory and quality characterization gaps for nanomedicines in Europe, highlighting the need for AI-driven predictive modeling and standardized frameworks.

Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges

Discussion

Member takes

Implication

Key Points

Cite This Study

Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider